<DOC>
	<DOC>NCT00465270</DOC>
	<brief_summary>The purpose of this study is to investigate whether percutaneous Patent Foramen Ovale (PFO) closure, using the AMPLATZER PFO Occluder, is superior to current standard of care medical treatment in the prevention of recurrent embolic stroke.</brief_summary>
	<brief_title>RESPECT PFO Clinical Trial</brief_title>
	<detailed_description>The AMPLATZER PFO Occluder is a percutaneous, transcatheter occlusion device intended for the non-surgical closure of patent foramen ovale in subjects who have had a cryptogenic stroke due to presumed paradoxical embolism within the last 270 days.</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<criteria>Subjects who have had a cryptogenic stroke within the last 270 days Subjects who have been diagnosed with a Patent Foramen Ovale (PFO) Subjects willing to participate in followup visits Subjects with intracardiac thrombus or tumor Subjects who have an acute or recent (within 6 months) myocardial infarction or unstable angina Subjects with left ventricular aneurysm or akinesis Subjects with atrial fibrillation/atrial flutter (chronic or intermittent) Subjects with another source of right to left shunt identified at baseline, including an atrial septal defect and/or fenestrated septum Subjects with contraindication to aspirin or Clopidogrel therapy Pregnant or desire to become pregnant within the next year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Cryptogenic</keyword>
	<keyword>Stroke</keyword>
	<keyword>PFO</keyword>
</DOC>